Cipla Limited

U & I Pharmaceuticals, Ltd.

Yusuf Khwaja Hamied

Dharmaraj Ramachandra Rao

Rajendra Narayanrao Kankan

Dharmaraj R Rao

Rajendra N Kankan

Dhanmaraj Ramachandra Rao

Rajendra Narayaurao Kankan

A process for making opticallyOpticallypure (R) and (S) salbutamolcomprises obtaining the (R) or (S) isomer of either salbutamol or a salbutamol precursor in substantially optically pure formis obtainedby resolving a racemic or optically impure mixture of enantiomers of salbutamol or ofsaida salbutamolprecursor with either (L) or (D) tartaric acid, and where necessary converting saidisomer of saidprecursor into either (R) or (S) salbutamol respectively; then optionally converting said optically pure (R) and/or (S) salbutamol into a pharmaceutically acceptable salt.

Process for preparing isomers of salbutamol

A process for making optically pure (R) and (S) salbutamol comprises obtaining the (R) or (S) isomer of either salbutamol or a salbutamol precursor in substantially optically pure form by resolving a racemic or optically impure mixture of enantiomers of salbutamol or of said precursor with either (L) or (D) tartaric acid, and where necessary converting said isomer of said precursor into either (R or (S) salbutamol respectively; then optionally converting said optically pure (R) and/or (S) salbutamol into a pharmaceutically acceptable salt.

A pharmaceutically acceptable alendronate salt in an amorphous form.

Pharmaceutically acceptable alendronate salts in amorphous form

Pharmaceutical compositions containing Form III, Form IV, Form V olanzapine and/or pharmaceutically acceptable salts thereof. The pharmaceutical compositions are useful for the treatment of psychotic conditions, mild anxiety and gastrointestinal conditions. In particular, the compositions are useful for treating schizophrenia and related disorders, acute mania, Bipolar I Disorder, psychotic mood disorder and psychosis in patients with Alzheimer's disease.

Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof

Citalopram and other phthalanes are made by reacting a salt of a compound of formula (II) where Ris halogen and Ris halogen, trifluoromethyl, cyano or R&#x2014;CO&#x2014; where R is a Calkyl group, with cuprous cyanide.

Preparation of phthalanes

The invention provides three new polymorphic forms of 2-methyl-4-&lsqb;4-methyl-1-piperazinyl&rsqb;-10H-thieno&lsqb;2,3b&rsqb;&lsqb;1,5&rsqb;benzodiazepine (Olanzapine) (Formula A), the process for preparing the new polymorphs and pharmaceutical compositions containing the polymorphs. The new polymorphic forms of olanzapine are useful for the treatment of psychotic conditions, mild anxiety and gastrointestinal conditions.

Growing community of inventors

Mumbai, India

Yusuf Khwaja Hamied